Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis

Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis

This review compares cytotoxic drugs, targeted therapies, and immunotherapies with regard to mechanisms and side effects. Targeted therapies relate to small molecule inhibitors. Immunotherapies include checkpoint inhibitory antibodies, chimeric antigen receptor (CAR) T-cells, cancer vaccines, and on...

Full description

Bibliographic Details
Main Author:	Volker Schirrmacher
Format:	Article
Language:	English
Published:	MDPI AG 2020-03-01
Series:	Biomedicines
Subjects:	targeted therapy immunotherapy oncolytic virus cancer vaccine adverse events small molecule inhibitor car t cell checkpoint inhibitor monoclonal antibody
Online Access:	https://www.mdpi.com/2227-9059/8/3/61

Similar Items

The Evolution of Cancer Immunotherapy
by: Meshaal Khan, et al.
Published: (2021-06-01)

The Intriguing History of Cancer Immunotherapy
by: Paula Dobosz, et al.
Published: (2019-12-01)

Oncolytic Viruses: Therapeutics With an Identity Crisis
by: Caroline J. Breitbach, et al.
Published: (2016-07-01)

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy
by: Yaqi Zhao, et al.
Published: (2021-07-01)

Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination
by: Mizuho Sato-Dahlman, et al.
Published: (2020-05-01)

Combination strategies to maximize the benefits of cancer immunotherapy
by: Shaoming Zhu, et al.
Published: (2021-09-01)

Emerging agents and regimens for multiple myeloma
by: Yang Yang, et al.
Published: (2020-11-01)

Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy
by: Hong-My Nguyen, et al.
Published: (2020-02-01)

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment
by: Tao Shi, et al.
Published: (2020-04-01)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
by: Antonio Marchini, et al.
Published: (2016-01-01)

Immunotherapy in Glioblastoma: A Clinical Perspective
by: Nicolas Desbaillets, et al.
Published: (2021-07-01)

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
by: Victor Cervera-Carrascon, et al.
Published: (2020-01-01)

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
by: Sampath P, et al.
Published: (2015-06-01)

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors
by: Chang-Myung Oh, et al.
Published: (2020-10-01)

Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
by: Nicholas Gravbrot, et al.
Published: (2019-10-01)

Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers
by: Dörthe Masemann, et al.
Published: (2021-01-01)

Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)
by: Shuguang Zuo, et al.
Published: (2021-02-01)

Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
by: S. Feola, et al.
Published: (2018-08-01)

Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
by: Christopher J. LaRocca, et al.
Published: (2018-11-01)

Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma
by: Darrin V. Bann, et al.
Published: (2016-09-01)

Immunotherapy in Multiple Myeloma
by: Cinnie Yentia Soekojo, et al.
Published: (2020-03-01)

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes
by: Alexander Malogolovkin, et al.
Published: (2021-06-01)

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
by: Amanda Rosewell Shaw, et al.
Published: (2018-09-01)

Clinical development of targeted and immune based anti-cancer therapies
by: N. A. Seebacher, et al.
Published: (2019-04-01)

Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
by: Emilie Alard, et al.
Published: (2020-07-01)

Cancer Immunotherapy and the Immune Response in Follicular Lymphoma
by: Frank Stenner, et al.
Published: (2018-06-01)

Current Trends in Cancer Immunotherapy
by: Ivan Y. Filin, et al.
Published: (2020-12-01)

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
by: Delong Liu
Published: (2019-11-01)

Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
by: María Florencia Mercogliano, et al.
Published: (2021-02-01)

From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review
by: Lukasz Kuryk, et al.
Published: (2020-10-01)

Emerging therapies for non-small cell lung cancer
by: Chao Zhang, et al.
Published: (2019-04-01)

Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
by: Bharat Burman, et al.
Published: (2020-11-01)

Oncolytic Virotherapy: The Cancer Cell Side
by: Marcelo Ehrlich, et al.
Published: (2021-02-01)

Challenges and Opportunities for Effective Cancer Immunotherapies
by: Clare Y. Slaney, et al.
Published: (2020-10-01)

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
by: Natalie S. Grover, et al.
Published: (2015-09-01)

Current Immunotherapeutic Strategies for the Treatment of Glioblastoma
by: Mark Dapash, et al.
Published: (2021-09-01)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
by: Alessandro Isidori, et al.
Published: (2021-05-01)

New Immunotherapy Strategies in Breast Cancer
by: Lin-Yu Yu, et al.
Published: (2017-01-01)

PD-L1 as a Potential Target in Cancer Therapy (Review)
by: N. N. Andrusova, et al.
Published: (2021-02-01)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020-09-01)